NUR 600 Advanced Clinical Pharmacology Actual Exam
Prep Document | 2026/2027 Edition | 250 Verified Questions
NUR 600 Advanced Clinical Pharmacology Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers covering
all major topics in advanced clinical pharmacology for graduate nursing students. Designed to align
with the 2026/2027 academic year curriculum, it provides detailed rationales and evidence-based
explanations to enhance understanding and retention. Ideal for advanced practice nursing students
preparing for the NUR 600 actual exam.
Abstract:
This examination preparation resource for NUR 600 Advanced Clinical Pharmacology is meticulously compiled to
reflect the 2026/2027 academic year standards for graduate nursing programs. It features 250 meticulously
verified questions that encompass core pharmacokinetic and pharmacodynamic concepts, drug classification,
therapeutic applications, and patient safety considerations. Each question is accompanied by a comprehensive
rationale that elucidates the correct answer and addresses common misconceptions, leveraging the most recent
clinical practice guidelines and pharmacological research. The document is structured to facilitate systematic
review, with content areas weighted according to typical exam emphasis, including cardiovascular, endocrine,
neurologic, antimicrobial, and pain management pharmacology. Additionally, it includes updates on emerging
therapies and regulatory changes, ensuring relevance for advanced practice nursing students. The abstract
underscores the document's utility as a high-fidelity simulation of the actual exam, aiming to bolster confidence
and clinical reasoning skills through rigorous practice and detailed feedback.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic and Cardiovascular 41-80 Adrenergic agonists/antagonists, cholinergic 16%
Pharmacology agents, antihypertensives, antiarrhythmics,
anticoagulants
Endocrine and Metabolic 81-120 Diabetes medications, thyroid hormones, 16%
Pharmacology corticosteroids, bone metabolism agents
Neurologic and Psychiatric 121-160 Antidepressants, antipsychotics, 16%
Pharmacology antiepileptics, Parkinson's disease drugs,
migraine therapies
Antimicrobial Therapy 161-200 Antibiotics, antivirals, antifungals, 16%
resistance mechanisms, stewardship
principles
Pain Management and Special 201-250 Opioid analgesics, non-opioid analgesics, 20%
Populations adjuvant therapies, pediatric/geriatric
considerations, pregnancy/lactation
Page 1
,Q1. A patient with chronic kidney disease (eGFR 28 mL/min/1.73m2) requires pain management.
Which opioid analgesic is most appropriate due to its lack of active metabolites that accumulate in
renal impairment?
A. Morphine
B. Hydromorphone
C. Codeine
D. Meperidine
Correct Answer: B. Hydromorphone
Rationale: Hydromorphone is preferred because it has no active metabolites and is primarily metabolized
in the liver; its clearance is less affected by renal impairment. Morphine produces
morphine-6-glucuronide, an active metabolite that accumulates in renal failure, increasing toxicity risk.
Codeine relies on CYP2D6 conversion to morphine and has active metabolites. Meperidine's metabolite
normeperidine accumulates, causing neurotoxicity.
Why Wrong:
A - Morphine's active metabolite (morphine-6-glucuronide) accumulates in renal impairment,
increasing risk of respiratory depression.
C - Codeine requires hepatic conversion to morphine and has active metabolites that can accumulate
in renal impairment.
D - Meperidine's metabolite normeperidine accumulates and can cause neurotoxicity (seizures) in
renal impairment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19, 20.
Q2. Which of the following best explains why a patient with a history of myocardial infarction and
heart failure with reduced ejection fraction (HFrEF) should receive both a beta-blocker and an
ACE inhibitor?
A. Beta-blockers increase heart rate, counteracting bradycardia from ACE inhibitors.
B. ACE inhibitors block the sympathetic nervous system, enhancing the negative inotropic effect of
beta-blockers.
C. Beta-blockers reduce renin release, and ACE inhibitors block angiotensin II, providing synergistic
neurohormonal antagonism.
D. ACE inhibitors prevent cough, a common side effect of beta-blockers.
Correct Answer: C. Beta-blockers reduce renin release, and ACE inhibitors block angiotensin II,
providing synergistic neurohormonal antagonism.
Rationale: Beta-blockers inhibit sympathetic drive and reduce renin release, while ACE inhibitors
suppress angiotensin II formation. This dual blockade of the renin-angiotensin-aldosterone system
(RAAS) and sympathetic nervous system reduces morbidity and mortality in HFrEF. Option A is incorrect
because beta-blockers decrease heart rate. Option B is misleading; ACE inhibitors do not block the SNS.
Option D is false; cough is associated with ACE inhibitors, not beta-blockers.
Why Wrong:
A - Beta-blockers lower heart rate, not increase it, and ACE inhibitors do not cause bradycardia as a
prominent effect.
B - ACE inhibitors primarily block RAAS, not the sympathetic nervous system, and their
combination with beta-blockers is synergistic, not antagonistic.
D - Cough is a common side effect of ACE inhibitors, not beta-blockers; this statement incorrectly
associates cough with beta-blockers.
Page 2
,Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43, 44.
Page 3
, Q3. A patient is receiving vancomycin for a methicillin-resistant Staphylococcus aureus (MRSA)
infection. On day 4, serum trough concentration is 25 mcg/mL (desired 15-20 mcg/mL). What is the
most appropriate next step?
A. Continue current dose and monitor renal function daily.
B. Increase the dose to achieve a higher trough to improve efficacy.
C. Hold the next dose, then decrease the dose or lengthen the dosing interval.
D. Add gentamicin for synergistic coverage.
Correct Answer: C. Hold the next dose, then decrease the dose or lengthen the dosing interval.
Rationale: The trough is above the therapeutic range, increasing nephrotoxicity risk. The standard
approach is to hold the next dose and adjust downward. Continuing the dose or increasing it would
elevate risk. Adding gentamicin without indication is unwarranted and increases nephrotoxicity.
Why Wrong:
A - Continuing the same dose with a supratherapeutic trough increases the risk of nephrotoxicity
without additional benefit.
B - Increasing the dose would worsen supratherapeutic levels and toxicity risk.
D - Adding gentamicin is not indicated for MRSA and would increase nephrotoxicity, especially
with elevated vancomycin levels.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 78, 79.
Q4. A patient with type 2 diabetes has inadequate glycemic control on metformin and sitagliptin.
HbA1c is 9.2%. The patient has chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m2) and a
BMI of 32 kg/m2. Which of the following agents would be most appropriate to add?
A. Pioglitazone
B. Canagliflozin
C. Insulin glargine
D. Glipizide
Correct Answer: B. Canagliflozin
Rationale: Canagliflozin (SGLT-2 inhibitor) offers glycemic control, weight loss, and
cardiovascular/renal benefits, and can be used with dose adjustment at eGFR 45. Pioglitazone may cause
fluid retention and weight gain. Insulin glargine is effective but may cause weight gain and requires
titration. Glipizide can cause weight gain and hypoglycemia, and its use is less favored in CKD due to
accumulation risk.
Why Wrong:
A - Pioglitazone can cause fluid retention and weight gain, and its efficacy is limited in advanced
CKD.
C - Insulin glargine is effective but can lead to weight gain and requires careful titration; it does not
have the renal protective benefits of SGLT-2 inhibitors.
D - Glipizide increases risk of hypoglycemia and weight gain; its active metabolites may accumulate
in CKD.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56, 57.
Page 4
Prep Document | 2026/2027 Edition | 250 Verified Questions
NUR 600 Advanced Clinical Pharmacology Exam 2026-2027 QUESTIONS AND ANSWERS ALREADY GRADED
A+. 100% Verified Solutions | Updated Per Latest Guidelines | Graded A+
This comprehensive exam preparation document contains 250 verified questions and answers covering
all major topics in advanced clinical pharmacology for graduate nursing students. Designed to align
with the 2026/2027 academic year curriculum, it provides detailed rationales and evidence-based
explanations to enhance understanding and retention. Ideal for advanced practice nursing students
preparing for the NUR 600 actual exam.
Abstract:
This examination preparation resource for NUR 600 Advanced Clinical Pharmacology is meticulously compiled to
reflect the 2026/2027 academic year standards for graduate nursing programs. It features 250 meticulously
verified questions that encompass core pharmacokinetic and pharmacodynamic concepts, drug classification,
therapeutic applications, and patient safety considerations. Each question is accompanied by a comprehensive
rationale that elucidates the correct answer and addresses common misconceptions, leveraging the most recent
clinical practice guidelines and pharmacological research. The document is structured to facilitate systematic
review, with content areas weighted according to typical exam emphasis, including cardiovascular, endocrine,
neurologic, antimicrobial, and pain management pharmacology. Additionally, it includes updates on emerging
therapies and regulatory changes, ensuring relevance for advanced practice nursing students. The abstract
underscores the document's utility as a high-fidelity simulation of the actual exam, aiming to bolster confidence
and clinical reasoning skills through rigorous practice and detailed feedback.
Content Area Overview:
Content Area Questions Key Topics Weight
Pharmacokinetics and 1-40 Absorption, distribution, metabolism, 16%
Pharmacodynamics excretion, receptor theory, dose-response
relationships
Autonomic and Cardiovascular 41-80 Adrenergic agonists/antagonists, cholinergic 16%
Pharmacology agents, antihypertensives, antiarrhythmics,
anticoagulants
Endocrine and Metabolic 81-120 Diabetes medications, thyroid hormones, 16%
Pharmacology corticosteroids, bone metabolism agents
Neurologic and Psychiatric 121-160 Antidepressants, antipsychotics, 16%
Pharmacology antiepileptics, Parkinson's disease drugs,
migraine therapies
Antimicrobial Therapy 161-200 Antibiotics, antivirals, antifungals, 16%
resistance mechanisms, stewardship
principles
Pain Management and Special 201-250 Opioid analgesics, non-opioid analgesics, 20%
Populations adjuvant therapies, pediatric/geriatric
considerations, pregnancy/lactation
Page 1
,Q1. A patient with chronic kidney disease (eGFR 28 mL/min/1.73m2) requires pain management.
Which opioid analgesic is most appropriate due to its lack of active metabolites that accumulate in
renal impairment?
A. Morphine
B. Hydromorphone
C. Codeine
D. Meperidine
Correct Answer: B. Hydromorphone
Rationale: Hydromorphone is preferred because it has no active metabolites and is primarily metabolized
in the liver; its clearance is less affected by renal impairment. Morphine produces
morphine-6-glucuronide, an active metabolite that accumulates in renal failure, increasing toxicity risk.
Codeine relies on CYP2D6 conversion to morphine and has active metabolites. Meperidine's metabolite
normeperidine accumulates, causing neurotoxicity.
Why Wrong:
A - Morphine's active metabolite (morphine-6-glucuronide) accumulates in renal impairment,
increasing risk of respiratory depression.
C - Codeine requires hepatic conversion to morphine and has active metabolites that can accumulate
in renal impairment.
D - Meperidine's metabolite normeperidine accumulates and can cause neurotoxicity (seizures) in
renal impairment.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 19, 20.
Q2. Which of the following best explains why a patient with a history of myocardial infarction and
heart failure with reduced ejection fraction (HFrEF) should receive both a beta-blocker and an
ACE inhibitor?
A. Beta-blockers increase heart rate, counteracting bradycardia from ACE inhibitors.
B. ACE inhibitors block the sympathetic nervous system, enhancing the negative inotropic effect of
beta-blockers.
C. Beta-blockers reduce renin release, and ACE inhibitors block angiotensin II, providing synergistic
neurohormonal antagonism.
D. ACE inhibitors prevent cough, a common side effect of beta-blockers.
Correct Answer: C. Beta-blockers reduce renin release, and ACE inhibitors block angiotensin II,
providing synergistic neurohormonal antagonism.
Rationale: Beta-blockers inhibit sympathetic drive and reduce renin release, while ACE inhibitors
suppress angiotensin II formation. This dual blockade of the renin-angiotensin-aldosterone system
(RAAS) and sympathetic nervous system reduces morbidity and mortality in HFrEF. Option A is incorrect
because beta-blockers decrease heart rate. Option B is misleading; ACE inhibitors do not block the SNS.
Option D is false; cough is associated with ACE inhibitors, not beta-blockers.
Why Wrong:
A - Beta-blockers lower heart rate, not increase it, and ACE inhibitors do not cause bradycardia as a
prominent effect.
B - ACE inhibitors primarily block RAAS, not the sympathetic nervous system, and their
combination with beta-blockers is synergistic, not antagonistic.
D - Cough is a common side effect of ACE inhibitors, not beta-blockers; this statement incorrectly
associates cough with beta-blockers.
Page 2
,Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 43, 44.
Page 3
, Q3. A patient is receiving vancomycin for a methicillin-resistant Staphylococcus aureus (MRSA)
infection. On day 4, serum trough concentration is 25 mcg/mL (desired 15-20 mcg/mL). What is the
most appropriate next step?
A. Continue current dose and monitor renal function daily.
B. Increase the dose to achieve a higher trough to improve efficacy.
C. Hold the next dose, then decrease the dose or lengthen the dosing interval.
D. Add gentamicin for synergistic coverage.
Correct Answer: C. Hold the next dose, then decrease the dose or lengthen the dosing interval.
Rationale: The trough is above the therapeutic range, increasing nephrotoxicity risk. The standard
approach is to hold the next dose and adjust downward. Continuing the dose or increasing it would
elevate risk. Adding gentamicin without indication is unwarranted and increases nephrotoxicity.
Why Wrong:
A - Continuing the same dose with a supratherapeutic trough increases the risk of nephrotoxicity
without additional benefit.
B - Increasing the dose would worsen supratherapeutic levels and toxicity risk.
D - Adding gentamicin is not indicated for MRSA and would increase nephrotoxicity, especially
with elevated vancomycin levels.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 78, 79.
Q4. A patient with type 2 diabetes has inadequate glycemic control on metformin and sitagliptin.
HbA1c is 9.2%. The patient has chronic kidney disease stage 3 (eGFR 45 mL/min/1.73m2) and a
BMI of 32 kg/m2. Which of the following agents would be most appropriate to add?
A. Pioglitazone
B. Canagliflozin
C. Insulin glargine
D. Glipizide
Correct Answer: B. Canagliflozin
Rationale: Canagliflozin (SGLT-2 inhibitor) offers glycemic control, weight loss, and
cardiovascular/renal benefits, and can be used with dose adjustment at eGFR 45. Pioglitazone may cause
fluid retention and weight gain. Insulin glargine is effective but may cause weight gain and requires
titration. Glipizide can cause weight gain and hypoglycemia, and its use is less favored in CKD due to
accumulation risk.
Why Wrong:
A - Pioglitazone can cause fluid retention and weight gain, and its efficacy is limited in advanced
CKD.
C - Insulin glargine is effective but can lead to weight gain and requires careful titration; it does not
have the renal protective benefits of SGLT-2 inhibitors.
D - Glipizide increases risk of hypoglycemia and weight gain; its active metabolites may accumulate
in CKD.
Reference: Lehne, R.A. (2026). Pharmacology for Nursing Care, 12th Ed., Ch. 56, 57.
Page 4
